CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
(RTTNews) - Exicure, Inc. (XCUR), a biotechnology company, has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc., marking a major step in advancing its clinical ...
The company states: “Exicure (XCUR) has announced the signing of a Memorandum of Understanding, MOU, with GPCR Therapeutics on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of ...
Exicure (NASDAQ:XCUR) signed a MOU with GPCR Therapeutics aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR ...
REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results